Chaperone Atopy Treatment Begins Patient Dosing in US Phase 2 Clinical Trial

Chaperon announced on the 7th that it has started dosing patients in the US Phase 2 clinical trial of Nugel, which is being developed as an atopic dermatitis treatment.

Chaperon Logo
Photo by Chaperon

This clinical trial received approval for the trial plan from the US Food and Drug Administration (FDA) in September last year. The goal is to confirm the improvement effect on the Eczema Area and Severity Index (EASI score) in 210 patients with mild to moderate atopic dermatitis of various ethnicities. The trial is conducted in a double-blind, placebo-controlled manner. The clinical trial is expected to conclude in the first half of 2026. Currently, Phase 2 trials are also underway in Korea.

Nugel is an inflammation-regulating drug that treats atopic dermatitis based on its action on G protein-coupled receptor (GPCR) 19. GPCRs are receptors that detect external signals and bind to intracellular G proteins to deliver drugs inside the cells. Because of this mechanism, unlike competing drugs, Nugel is expected to act only on immune-related cells, resulting in fewer side effects. Additionally, since it increases the number of inflammation-suppressing cells in the skin, it is explained to be effective not only for atopic dermatitis but also for other skin diseases.

Seungyong Sung, CEO of Chaperon, said, “Along with Korea, we are very excited to officially start global clinical trials with the first patient enrollment in the US Phase 2 trial,” and added, “We will also promote Nugel’s entry into the global market and global technology transfer.”

This content was produced with the assistance of AI translation services.